Application of anterior sciatic nerve block with liposomal bupivacaine in lower leg fracture surgery: a randomized clinical trial

应用脂质体布比卡因进行前坐骨神经阻滞麻醉治疗下肢骨折:一项随机临床试验

阅读:3

Abstract

BACKGROUND: Postoperative acute pain management remains a critical challenge in orthopedic surgery. This study compared the analgesic efficacy of liposomal bupivacaine versus conventional ropivacaine when administered via an ultrasound-guided anterior sciatic nerve block in patients undergoing lower leg fracture surgery. METHODS: In a randomized, double-blinded trial, eighty adult patients scheduled for elective open reduction and internal fixation (ORIF) of lower leg fractures. Patients were randomized into Group LB (20 mL liposomal bupivacaine, 266 mg) or Group R (20 mL 0.5% ropivacaine). The primary outcome was postoperative pain scores (Visual Analog Scale, VAS) at 6 h (T1), 24 h (T2), 48 h (T3), and 72 h (T4). Secondary outcomes included perioperative opioid use, motor block onset time, Postoperative hospital stay, functional recovery (Barthel Index), and complications. RESULTS: Group LB exhibited significantly lower VAS scores at T2 (p < 0.001), T3 (p = 0.007), and T4 (p = 0.042), though with higher scores at T1 (p < 0.001). Postoperative hospital stay was shorter in Group LB (p = 0.021), and functional recovery at discharge (Barthel Index) was superior (p = 0.020). No significant differences in perioperative opioid use or complication rates were observed. CONCLUSIONS: Compared to ropivacaine, liposomal bupivacaine administered via anterior sciatic nerve block provided prolonged postoperative analgesia and was associated with improved functional recovery and shorter hospital stay in patients undergoing lower leg fracture surgery. TRIAL REGISTRATION: The study protocol was registered at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , ChiCTR2400084397, 15/05/2024).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。